Diaceutics (LON:DXRX) Shares Down 3.5% - Time to Sell?

Diaceutics PLC (LON:DXRX - Get Free Report)'s stock price traded down 3.5% on Wednesday . The company traded as low as GBX 137 ($1.68) and last traded at GBX 137 ($1.68). 168,225 shares changed hands during trading, an increase of 3% from the average session volume of 163,573 shares. The stock had previously closed at GBX 142 ($1.74).

Analysts Set New Price Targets

Several research analysts have recently commented on DXRX shares. Canaccord Genuity Group reaffirmed a "buy" rating and issued a GBX 160 ($1.97) price target on shares of Diaceutics in a report on Tuesday, December 17th. Canaccord Genuity Group restated a "buy" rating and issued a GBX 160 ($1.97) target price on shares of Diaceutics in a research note on Tuesday, December 17th.

Diaceutics Price Performance

The company has a market capitalization of £115.09 million, a P/E ratio of -4,541.67 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. The business has a 50 day simple moving average of GBX 130.24 and a 200-day simple moving average of GBX 128.62.

Insider Transactions at Diaceutics

In other news, insider Graham Paterson acquired 11,643 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were bought at an average price of GBX 138 ($1.70) per share, with a total value of £16,067.34 ($19,741.17). Insiders own 34.30% of the company's stock.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.